As SMN protein levels are known to be developmentally downregulated in a tissue-specific manner (51–53), we evaluate the amount of SMN protein in treated SMA mice relative to corresponding age-matched untreated animals. The gene discussed is SMN1; the disease is proximal spinal muscular atrophy.